Management Strategy of Testosterone Therapy

Course Overview

This course covers TRT management after the diagnostic work is already complete. The question is no longer whether testosterone can be prescribed. The question is whether it should be prescribed, what should be corrected first, how treatment should be structured, and how the patient should be monitored once therapy begins. Major guidelines continue to frame testosterone therapy as treatment for men with compatible symptoms and confirmed biochemical deficiency, not as a default response to vague complaints or isolated laboratory findings. [1,2]

The course is built around two patients. The first is the TRT-naive patient who needs a candidacy decision. The second is the transition patient who arrives already taking testosterone and carrying somebody else’s diagnosis, dosing pattern, assumptions, and complications into your practice. Across both groups, the governing principle is the same: TRT management is not the prescription. It is the stewardship.

Learning Objectives

After completing this course, clinicians should be able to:

➀ Distinguish the management strategy for the TRT-naive patient from the strategy for the transition patient already receiving testosterone.

➁ Explain why testosterone should not be the default first-line response to nonspecific symptoms.

➂ Conduct informed-consent counseling that frames TRT as chronic therapy requiring monitoring, adherence, and realistic expectations.

➃ Incorporate fertility assessment before treatment and identify when alternatives deserve consideration.

➄ Select a testosterone formulation based on control, predictability, practicality, and patient-specific factors.

➅ Build an early follow-up plan using symptom tracking, pharmacokinetic timing, laboratory reassessment, PSA planning, and ABCDS™ surveillance.

➆ Reset inherited protocols that do not hold up clinically.

Course Topics

The following topics will be covered in the course text, video, diagrams or downloadable documents:

➀ Scope Of The Management Framework

➁ Start With The Chief Complaint

➂ Why Testosterone Should Not Be The Default

➃ Informed Consent And Long-Term Commitment

➄ Fertility Assessment Before Treatment

➅ TRT As A Structured Therapeutic Trial

➆ Comprehensive Risk Discussion

➇ Selecting Testosterone Formulation

➈ Managing The Transition Patient

➉ Early Follow-Up And Longitudinal Stewardship

Video Lesson Takeaways

◉ Management begins after the history, physical examination, and laboratory workup have already been interpreted in context.

◉ The TRT-naive patient and the transition patient should not be managed with the same assumptions.

◉ Testosterone should not be the default answer to nonspecific symptoms when larger reversible pathology may be driving the presentation.

◉ Informed consent must frame TRT as chronic therapy requiring monitoring, adherence, and realistic expectations.

◉ Fertility has to be discussed before treatment because exogenous testosterone may suppress spermatogenesis.

◉ TRT should be treated as a structured therapeutic trial that continues only when benefit clearly outweighs risk.

◉ Erythrocytosis is a major management complication and should trigger broader reassessment.

◉ Injectable testosterone remains the most practical first-line formulation for many patients.

◉ Transition patients require a real protocol reset, not blind continuation.

◉ TRT management is longitudinal medical stewardship.

➀ Scope Of The Management Framework

Management starts when the clinician has enough information to make a real decision. That is where many TRT cases go wrong. The symptoms are real, the testosterone value looks low enough to tempt action, and the visit starts leaning toward treatment before the clinician has actually decided what problem is being treated.

In the TRT-naive patient, the job is candidacy analysis. In the transition patient, the job is reconstruction. You are deciding whether the original diagnosis was sound, whether the patient is truly benefiting, whether the protocol is rational, and whether prior complications were normalized instead of managed. The benefits must outweigh the risks for every case. The AUA guideline and the Endocrine Society guideline both support diagnosis and treatment only in the proper clinical context rather than through symptom matching alone. [1,2]

Starting TRT means the clinician becomes the prescriber who first exposes the patient to exogenous androgens, which carries long-term responsibility for counseling, monitoring, and risk disclosure.

➁ Start With The Chief Concern

The chief concern should remain the anchor. A better one separates low libido from erectile dysfunction, fatigue from sleep disruption, mood change from depression, and body-composition frustration from true androgen deficiency. [1,5]

Nonspecific symptoms are common and misleading. A man with obesity, insulin resistance, poor sleep, antidepressant exposure, alcohol overuse, vascular disease, or life stress can sound like a classic TRT candidate if the clinician listens loosely. Testosterone deficiency guidance and erectile dysfunction guidance both point back to broader clinical evaluation rather than single-cause thinking. [1,2,5]

➂ Why Testosterone Should Not Be The Default

Many clinicians still mistake symptom burden for proof of androgen deficiency and a borderline testosterone value for permission to prescribe. That shortcut creates unnecessary long-term treatment.

Symptoms commonly blamed on low testosterone overlap with obesity, obstructive sleep apnea, insulin resistance, type 2 diabetes, depression, anxiety, medication effects, alcohol misuse, and chronic sleep restriction. The Endocrine Society recommends diagnosing hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone concentrations. The AUA guideline uses the same basic logic. [1,2]

The management question is not “Can I start TRT?” The better question is “What is the dominant correctable pathology in this patient right now?” If it is untreated sleep apnea, worsening metabolic disease, major weight gain, or medication-related sexual dysfunction, that deserves direct treatment first. Some of those men will still need TRT. Others will look very different once the larger problem is addressed. [1,2] TRT decisions should be coordinated with primary care and relevant specialists when cardiometabolic, psychiatric, or systemic disease contributes to the presentation.

➃ Informed Consent And Long-Term Commitment

The consent discussion should make three things unmistakable. TRT may become long-term therapy. It may suppress endogenous production. It requires monitoring and reassessment. [1,2,8]

Patients should also understand the financial and logistical burden of long-term therapy, including ongoing visits, laboratory monitoring, and medication costs. They do not get to self-adjust the dose casually and still expect clear interpretation. Endocrine Society guidance and performance measures both support repeat testing and structured monitoring after initiation rather than casual continuation once therapy starts. [2,8]

Testosterone may help libido, energy, sexual function, mood, or recovery. It does not guarantee restoration of every lost trait or every concern the patient initially presented with.

➄ Fertility Assessment Before Treatment

Fertility counseling should be done before treatment initiation, not after suppression has already occurred. The AUA/ASRM male infertility guideline advises clinicians to discuss the long-term impact of exogenous testosterone on spermatogenesis in men interested in current or future fertility. [3] A patient who says children are not a priority right now has not settled the issue. That remains one of the most common avoidable failures in front-end TRT management.

In selected men, alternatives such as clomiphene or enclomiphene may deserve consideration when preserving endogenous stimulation is indicated. That does not mean every patient concerned about fertility should be placed on a universal non-TRT protocol. [1,3]

➅ TRT As A Structured Therapeutic Trial

TRT should be framed as a structured therapeutic trial. That language protects clinical judgment and improves follow-up. A six- to twelve-month trial is reasonable when the indication is sound and the patient has been counseled properly. Continuation should depend on whether benefit exceeds risk and whether the original symptom cluster and functional impairment improve. A higher testosterone level is not enough. The major guidelines support reassessing symptoms as well as testosterone levels after initiation. [1,2,8]

This is where many clinicians get passive. They normalize the lab, leave the patient on therapy, and quietly redefine that as success. TRT should continue because the patient is doing meaningfully better, not because stopping would be inconvenient.

➆ Comprehensive Risk Discussion

Risk counseling should include acne, mood volatility, and irritability. Hair loss is another androgen-related effect that some patients consider when deciding whether to start treatment. Gynecomastia risk and estrogen-related symptoms should be discussed without teaching estrogen panic. Blood pressure, lipids, cardiovascular context, erythrocytosis, iron balance, and prostate surveillance all belong in the conversation. [1,2]

Recent evidence has reshaped the cardiovascular discussion surrounding testosterone therapy. Following publication of the TRAVERSE trial, the FDA removed the boxed warning for major adverse cardiovascular events (MACE) from testosterone products, although a boxed warning for hypertension was added for oral testosterone undecanoate. Epidemiologic data continue to show an association between low testosterone and cardiovascular disease, but the cardiovascular safety of TRT itself remains incompletely defined. In TRAVERSE, testosterone therapy was noninferior to placebo for MACE in men with hypogonadism and elevated cardiovascular risk who were medically managed. The study primarily used transdermal testosterone gel with dose adjustment above 750 ng/dL, and median testosterone levels in the treatment arm remained below 400 ng/dL. These conditions differ from many clinical practices, where injectable testosterone cypionate or enanthate is commonly used and treatment targets may be higher. Importantly, most participants were treated with lipid-lowering therapy, many received aspirin, and blood pressure was well controlled, factors that likely contributed to the observed safety outcomes. While TRAVERSE significantly advanced understanding of TRT and cardiovascular risk, further studies are needed to evaluate commonly used injectable regimens under real-world monitoring conditions. Additional TRAVERSE substudies have examined fracture risk in hypogonadal men. [2,4,9,10]

Erythrocytosis is one of the most important management complications. A rising hematocrit should trigger reassessment of indication, dose, formulation, interval, sleep apnea risk, smoking exposure, and iron balance. It should not trigger phlebotomy alone. Recent reviews describe testosterone-associated erythrocytosis as common and clinically significant. [1,2,6]

The prostate discussion should be straightforward. Current data do not show that TRT causes new prostate cancer, but baseline PSA assessment and appropriate follow-up remain standard parts of responsible care. Randomized prostate safety data in appropriately screened hypogonadal men found low rates of high-grade or any prostate cancer and other prostate events, without significant differences between testosterone and placebo groups. [1,2,7]

➇ Selecting Testosterone Formulation

Injectable testosterone remains the gold standard for many patients because it is effective, affordable, and titratable. It can be used intramuscularly or subcutaneously. It gives the clinician real control over the protocol instead of forcing interpretation through variable absorption or cumbersome delivery systems. Major guidelines and contemporary reviews still keep injections central in routine management. [1,2,12]

Microdosing can be better than widely spaced injections for some patients because wide peaks and troughs can create more symptoms. However, it comes with its own challenges due to injection burden. Clinicians should individualize dosing intervals using shared decision making [1,12].

Transdermal therapy is useful when noninvasive delivery matters, but its risks include transfer risk, adherence, and variable absorption. Pellets trade convenience for weak kinetic control. Oral testosterone undecanoate has a legitimate role, but food dependence, cost, and adherence narrow its use. Nasal testosterone is short acting and often cumbersome in routine use. Contemporary pharmacology reviews and clinical trial data support these route-specific tradeoffs [1,2,12].

➈ Managing The Transition Patient

Many transition patients arrive from wellness clinics, telemedicine TRT programs, or bodybuilding-style protocols that were not built around formal diagnostic criteria or longitudinal medical monitoring. Transition patients should not be continued blindly. A transferred patient may arrive overtreated, undertreated, poorly counseled, mistrustful, or simply confused. The new clinician should reassess diagnosis, indication, protocol, complications, and expectations from the ground up. [1,2]

This is where poor care patterns should be named plainly. Estradiol is often overmanaged. Higher weekly testosterone is often treated as inherently better. The reset should normalize dosing, simplify the regimen, rebuild monitoring, and correct misinformation without alienating the patient [1,2]. The transition visit should also focus on why the patient came for new care. Rising hematocrit. Libido failure. Blood pressure drift. Fear. Confusion. Protocol fatigue. If the reason the patient sought new care is not identified, the revised plan may still miss the patient’s chief concern.

➉ Early Follow-Up And Longitudinal Stewardship

Expectations should be set early. Some patients notice subtle changes in the first few weeks. More stable benefits often emerge over the next one to three months. That timeline should be taught clearly because unrealistic early expectations drive unnecessary dose changes and poor adherence. [2,8]

Early access to the clinician or care team can help triage safety concerns. Mood changes, fluid shifts, acne, blood pressure changes, perceived estrogen symptoms, and injection confusion all show up early. If the practice disappears during that phase, patients improvise.

Laboratory timing should reflect pharmacokinetics. For injectable regimens, meaningful reassessment often sits around six to eight weeks. Nadir labs should be drawn on the scheduled injection day before the dose is taken. Typical labs include total testosterone, free testosterone, CBC, CMP, and iron studies, with estradiol and PSA handled according to the clinical context. Follow-up testosterone testing within the first several months is explicitly supported by Endocrine Society performance measures. [1,2,8]

COURSE SUMMARY

Good TRT management is defined less by the starting dose than by the quality of judgment around indication, reversibility, fertility, monitoring, and follow-up. That is especially true in transfer-of-care cases. Many patients arrive carrying somebody else’s protocol and somebody else’s blind spots. Rebuilding those cases is often the first responsible care they have received. The core lesson remains the right one. TRT management is not the prescription. It is the stewardship.

REFERENCES

Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
Brannigan RE, Hermanson L, Kaczmarek J, et al. Updates to male infertility: AUA/ASRM guideline (2024). J Urol. 2024;212(6):789-799
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117.
Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641.
Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024;13(10):e240283.
Bhasin S, Travison TG, Pencina KM, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6(12):e2348692.
Endocrine Society. Diagnosis, treatment, and follow-up of men with androgen deficiency: performance measures. Published 2018. https://www.endocrine.org
Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203-211.
Grossmann M. Testosterone treatment and fractures in older men. N Engl J Med. 2024;390(3):270-272.
Pencina KM, Travison TG, Artz AS, et al. Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6(10):e2340030.
Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment, and monitoring of functional hypogonadism in males. Andrology. 2020;8(5):970-987.

Management Strategy of Testosterone Therapy

Course Overview

Learning Objectives

Course Topics

007 Management Strategy of Testosterone Therapy

Video Lesson Takeaways

➀ Scope Of The Management Framework

➁ Start With The Chief Concern

➂ Why Testosterone Should Not Be The Default

➃ Informed Consent And Long-Term Commitment

➄ Fertility Assessment Before Treatment

➅ TRT As A Structured Therapeutic Trial

➆ Comprehensive Risk Discussion

➇ Selecting Testosterone Formulation

➈ Managing The Transition Patient

➉ Early Follow-Up And Longitudinal Stewardship

Recommended Grand Rounds Case Reviews

Advanced Clinical Training Insights